Product Name: DRAK2 antibody [EPR3163Y]
Applications: ICC/IF, IP, WB
Predicted Target Size:
Positive Controls:
Form Supplied: Liquid
Concentration:
Purification: Tissue culture supernatant
Full Name: serine/threonine kinase 17b
Background: DRAK2 belongs to a family of novel serine/threonine kinases whose catalytic domains are related to that of death-associated protein kinase involved in apoptosis. DRAK2 is composed of an N-terminal catalytic domain and a C-terminal domain that is responsible for regulation of kinase activity. DRAK2 is exclusively localized to the nucleus and overexpression of DRAK2 induces the morphological changes of apoptosis in NIH 3T3 cells, suggesting the role of DRAK2 in apoptotic signaling.
Synonyms: DRAK2
Cellular Localization:
CAS NO: 120011-70-3
Product: Ulipristal (acetate)
Host: Rabbit
Clonality: Monoclonal
Isotype: IgG
Immunogen: A synthetic peptide corresponding to residues 200 – 300 aa in human DRAK2 was used as an immunogen.
Antigen Species: Human
Species Reactivity: Human, Mouse
Conjugation: Unconjugated
Storage Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Storage Instruction: Store at -20 °C. Stable for 12 months from date of receipt.
Notes: For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,488.
Specificity: GTX62735 is specific for Human DRAK2.
PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/15848394?dopt=Abstract
